{
    "clinical_study": {
        "@rank": "23402", 
        "arm_group": [
            {
                "arm_group_label": "Subjects receiving Ranibizumab", 
                "description": "150 Subjects diagnosed with Neovascular Age-Related Macular Degeneration receiving Ranibizumab 0.5 mg administered by intravitreal injection."
            }, 
            {
                "arm_group_label": "Subjects receiving Aflibercept", 
                "description": "150 Subjects diagnosed with Age-related Macular Degeneration receiving Aflibercept 2 mg administered by intravitreal injection"
            }
        ], 
        "brief_summary": {
            "textblock": "This open-label, Phase IV prospective, observational study will evaluate patients, who have\n      been diagnosed with Neovascular Age-Related Macular Degeneration and have previously\n      received either a standard intravitreal injection of ranibizumab or aflibercept, in order to\n      get and compare information regarding post-injection inflammatory (irritation in the eye)2-3\n      days post-injection.\n\n      Additionally, patients will be evaluated for visual acuity and pain 2-3 days post-injection."
        }, 
        "brief_title": "Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Intravitreal Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients.", 
        "condition": "Neovascular Age Related Macular Degeneration", 
        "condition_browse": {
            "mesh_term": [
                "Inflammation", 
                "Macular Degeneration", 
                "Wet Macular Degeneration"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients, age 65 to 90, with Neovascular Age-Related Macular Degeneration who present for\n      treatment with intravitreal ranibizumab or aflibercept will be selected in this study.  300\n      subjects from one site in the United States will be enrolled.\n\n      Inclusion Criteria:\n\n        -  Ability to provide written informed consent and comply with study\n\n        -  Age 65-90 years\n\n        -  Diagnosis of Neovascular Age-Related Macular Degeneration who present for treatment\n           with intravitreal ranibizumab or aflibercept\n\n      Exclusion Criteria:\n\n        -  Previous intraocular inflammation\n\n        -  Treatment with systemic anti-inflammatory agents\n\n        -  Known systemic autoimmune diseases\n\n        -  Treatment with intraocular steroids in the past 3 months\n\n        -  History of intraocular surgery in the past 3 months\n\n        -  Age greater than 90 years\n\n        -  Patients who were switched between either therapies in the past 3 months"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Ability to provide written informed consent and comply with study assessments for the\n             full duration of the study\n\n          -  Age 65-90 years\n\n          -  Diagnosis or Neovascular Age-Related Macular Degeneration who present for treatment\n             with intravitreal ranibizumab or aflibercept\n\n        Exclusion Criteria:\n\n          -  Previous intraocular inflammation\n\n          -  Treatment with systemic anti-inflammatory agents\n\n          -  Known systemic autoimmune diseases\n\n          -  Treatment with intraocular steroids in the past 3 months\n\n          -  History of intraocular surgery in the past 3 months\n\n          -  Age greater than 90 years\n\n          -  Patients who were switched between either therapies in the past 3 months"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "65 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Private practice patients referred to retinal specialist for treatment of Neovascular\n        Age-Related Macular Degeneration"
            }
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01942213", 
            "org_study_id": "NJRetina ML28942", 
            "secondary_id": "NJRetina Observational ML28942"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Macular", 
            "Degeneration", 
            "Age related", 
            "Neovascular"
        ], 
        "lastchanged_date": "June 2, 2014", 
        "location": {
            "contact": {
                "email": "rothretina@gmail.com", 
                "last_name": "Daniel Roth, MD", 
                "phone": "732-220-1600"
            }, 
            "facility": {
                "address": {
                    "city": "Toms River", 
                    "country": "United States", 
                    "state": "New Jersey", 
                    "zip": "08755"
                }, 
                "name": "NJ Retina"
            }, 
            "investigator": {
                "last_name": "Daniel Roth, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "2", 
        "official_title": "Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Intravitreal Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients", 
        "other_outcome": {
            "description": "Pain will be measured on a standardized pain scale; Visual Function Questionaire -25 and a 0-10 numeric pain scale.", 
            "measure": "To evaluate patient's pain post-injection", 
            "safety_issue": "No", 
            "time_frame": "2-3 days post-injection"
        }, 
        "overall_contact": {
            "email": "rothretina@gmail.com", 
            "last_name": "Daniel Roth, MD", 
            "phone": "732-220-1600"
        }, 
        "overall_official": {
            "affiliation": "NJ Retina", 
            "last_name": "Daniel Roth, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "All eyes will be evaluated 2-3 days after injection and graded in terms of (a) aqueous cells, graded subjectively on a scale of 0-4, (b) aqueous flare, graded subjectively on a scale 0-4, (c) aqueous flare graded objectively with the FM-600 Kowa flare meter and (d) vitreous haze, graded subjectively on a scale of 0-4.", 
            "measure": "To evaluate post-intravitreal injection inflammatory response in patients receiving either ranibizumab or aflibercept.", 
            "safety_issue": "Yes", 
            "time_frame": "2-3 days after injection"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01942213"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Best corrected visual acuity will be assessed by the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study eye chart at a starting test distance of 4 meters.", 
            "measure": "To evaluate patients 2-3 days post-injection for best corrected visual acuity", 
            "safety_issue": "No", 
            "time_frame": "2-3 days post-injection"
        }, 
        "source": "NJ Retina", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "NJ Retina", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "June 2014"
    }
}